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The safetyand pharmacokinetics of the twoneutralizing human IgGl monoclonal antibodies
to cytomegalovirus (CMV) SDZ89-104 and 89-109 in bonemarrowtransplant (BM1)recipients
was assessed in an open phase I trial. Thirteen patients, 8 seropositive and 5 seronegative for
CMV, were treated withallogeneic or autologous bonemarrowtransplantation. SDZ89-104 was
given to 5 and SDZ 89-109 to 8 patients. Patientswere dividedinto high-and low-dose groups.
A fixed prestudy doseof 0.1 mglkgwasgiven4 daysbefore BMT. On days3, 17, 31,45, 59, and
73, patients were treated with either 0.5or 2 mglkgof the respective antibody. Results indicate
that doses of2 mglkgofSDZ89-104 or SDZ89-109 in alternating weekscan besafely administered
to BMTpatients. Serum trough levels measuredby antiidiotypeELISA were "'10 JLg/mi after
administrationof0.5mglkgand "'50 JLg/mi after treatment with2 mglkgofSDZ89-104 or SDZ
89-109. Highserumlevels defined byantiidiotypeELISA techniques closely paralleledincreased
neutralizing activity. Serum half-lives calculated from these data were "'6 days.
Human cytomegalovirus (CMV) causes most interstitial
pneumonias in bone marrow transplant (BMT) recipients, the
most frequent and serious infectious complication after al-
logeneic BMT. Despite all therapeutic efforts,mortality con-
sistently reaches 50% [1]. Thus, clinical interest has focused
on the prevention of CMV infection. Trials using human
hyperimmune globulin for prophylaxis of CMV disease have
had contradictory results [2]. Although the reasons for these
discrepancies are unclear, varying content of neutralizing an-
tibodies in different immunoglobulin preparations may be
responsible [3].
Monoclonal antibodies, in contrast, are highly standardiz-
able reagents with defined functional and pharmacokinetic
properties. The clinical applicationof murine monoclonalan-
tibodies, however, is limited by several obstacles. Frequent
administrationis required because of their short half-lives and
the rapid development of human anti-mouse antibodies can
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effectively neutralize the clinical effects of therapy [4, 5].
Moreover, mostmurine monoclonalantibodieslack important
immune effectorfunctions[6]. Human monoclonalantibodies
maybeless immunogenic, shouldhavelonger circulationhalf-
lives, and thus may be superior for prolonged treatment of
patients. We report here the results of the first clinical phase
I trial with human monoclonal antibodies in BMT patients.
Patients, Materials, and Methods
Humanmonoclonal antibodies neutralizing CMV designated SDZ
89-109 (formerlyEV2-7) andSDZ89-104 (formerlyEV1-15) were
established at theSandoz Research Institute. Both antibodies areof
IgGl isotype butcarrydifferent idiotypes. They were shown to neu-
tralize 50-100 times the IDso of laboratory CMV strains Towne,
Davis, andAD169 andfourclinical isolates in theabsence ofcom-
plement in concentrations as littleas 1 pg/ml (Scriba M, personal
communication). SDZ89-109 neutralizes by binding to an 82-kDa
protein, whereas SDZ89-104 binds to a disulfide-bonded complex
consisting of 58-, 107-, and 163-kDa proteins [7]. Thetarget anti-
genofSDZ89-104 hasbeenfurther characterized using cloned frag-
ments of gp58 of human CMV. These experiments demonstrated
that the binding structure for SDZ 89-109 is the same epitope on
gp58 (gpB) ofCMV thathasbeendescribed by Utzetal. [8](Mach
M, personal communication).
Fourfemale andnine male patients, 12-52years old(median, 28),
were studied. Eight were seropositive forCMV-specific antibodies
before allogeneic (8patients) andautologous BMT (5patients). Pa-
tients were treated witheitherSDZ89-104 or 89-109. Fourdays be-
fore BMT, all patients received 0.1 mg/kg. On days 3, 17, 31, 45,
59, and73 afterBMT, the patients received either0.5 or 2 mg/kg
ofdrugby intravenous infusion for30min(table 1). Blood samples
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Table 1. Serum levels and half-lives of human monoclonal antibodies SDZ 89-104 and 89-109
in bone marrow transplant (BMT) patients.
Idiotype level (ug/ml)
Monoclonal Peak level NeutralizationBefore administration
antibody, Dose after last Before After Half-life
patient (mg/kg) 2 Last dose first dose last dose (days)
SDZ 89-104
1 0.5 0 4.8 13.6 22.3 1:320 1:320 6.1
2 0.5 0 3.6 4.2 18.2 0 1:160 4.2
3 0.5 0 2.8 11.0 29.6 1:40 1:160 7.6
4 2 0 14.8 65.9 192.1 0 1:40 3.2
5 2 0 13.1 60.8 53.3 0 0 ND
SDZ 89-109
1 0.5 0.1 1.6 9.3 21.7 0 0 8.4
2 0.5 0 3.4 13.8 27.3 1:20 1:20 7.0
3 0.5 0.01 3.4 9.8 27.8 0 1:40 7.0
4 2 0 26.9 81.3 260.9 0 1:160 3.2
5 2 0.3 0.2* 53.2 99.8 1:10 1:80 3.7
6 2 0 6.7 29.0 86.1 1:40 1:80 8.3
7 2 0 3.5 t 23.6 0 1:80 ND
8 2 0 10.6 58.8 154.7 1:20 1:40 14.8
NOTE. ND = not done.
* Received only 0.1 mg/kg on day 3 after BMT.
t Received monoclonal antibody 3 days before BMT and on days 4 and 17 after transplantation only.
were taken at 0, 1,2, 12,24,48, 72, 96, 120, 144, and 264 h after
each administration. Vital signswere monitored hourly for the first
4 h after each infusionof the antibody.Blood counts, liver and kid-
ney function tests, and measurement of serum levelsof circulating
immune complexesand complement componentswere done twice
weekly.
Polyclonal antiidiotypic antibodies to SDZ 89-109 and 89-104 were
prepared by immunizing goats with intact IgG. Sera were affinity
purified on SDZ 89-109 or 89-104 coupledto cyanogen bromide-acti-
vatedsepharose(Pharmacia, Uppsala, Sweden).Antiidiotypic anti-
bodieswerecoupledto biotin following published standardmethods.
Wellsof ELISAplates(Nunc, Roskilde, Denmark)werecoatedwith
0.2 p.g of affinity-purified antiidiotypic antibodies to SDZ 89-109
or 89-104 (2 p.g/rlu). Plateswere washedand free-binding siteswere
saturated with 5% fetal calf serum in PBS and washedagain three
times. Patientsera (100 p.l) wereaddedin twofold dilutionstepsrang-
ing from 1:20 to 1:2560. After incubationfor 1 h at room tempera-
ture, theplateswerewashed fivetimesand incubated with 100 p.l/well
biotinylatedantiidiotypic antibodies for another hour. Every plate
containeda seriesof standards.After threemorewashings, theplates
weredevelopedwith peroxidase-conjugated avidin(VectorLabora-
tories, Burlingame, CA)and phenylendiamine (Fluka, Buchs,Swit-
zerland) as a substrate. Extinction was read at 492 nm in a standard
ELISAreader. The serum concentrationsof monoclonalantibodies
werecalculatedbylinear regressionanalysisof the logittransformed
optical density values, the standard curve serving as a reference.
The lower limit of detection of these assays was "'0.01 pg/ml.
A linear one-compartmentmodel was foundto be appropriate to
characterize the pharmacokineticsof both compounds. Even if the-
oretically the total eliminationcould be split into an early redistri-
bution phase and a terminal degradationphase, the raw data did not
support such behavior. In mathematical terms these concentra-
tion/time profiles are Cn(t) = A[(1 - e-nkT)/(1 - e-kT)]e-kT, which
describes the time course of drug concentration (C) of a one-
compartmentmodelafter repeateddosing. t is the timeelapsedsince
the nth dose wasadministered, T is the lengthof the dosage interval
(i.e., 14 days), A is a scaling factor that includesthe volumeof dis-
tribution and the dose administered, and k is the elimination rate
constant. In comparisonwiththe verylongelimination half-life given
by t'hk = 1 n(2)/k, the input was assumed to be a bolus injection
insteadof an infusion. For practical reasons the concentrationdata
of each dosing interval were divided by the respectivefactor (l -
e-nkT/1 - e-kT) that transformed the individual multiple dosing
profiles to single-dose profiles. For log-linear regression analysis
of the resulting profiles, all concentrations of a singlepatient were
merged, simulating a repeated single-dose measurement design.
CMV cultures on human foreskin fibroblasts were done weekly
fromurine, blood, andsalivabystandardmethods[9]. CMV-specific
antibodies weremeasured bycommercially available ELISAs (Medac,
Hamburg, FRG). Positivecultures from urine or blood or serocon-
version or a fourfoldincrease in ELISAtiters was considered labo-
ratory evidence of CMV infection. Presence of SDZ 89-109 and
89-104 in the serum did not interferewith the serologictests as sera
of seronegative patients remainednegative despitehighlevels ofSDZ
89-109 and 89-104. Before treatment, 12 h after the second, and
immediatelybefore and 12 h after the last dose of the antibodies,
serum samples were tested for neutralizing activity against CMV
by a microneutralization test [10].
Results
We first tested to see if the idiotypes were detectable in
randomly selected sera. One serum sample of 30 contained
low levels (0.05) p.g/ml)of the SDZ 89-104 idiotype. In con-
trast, 15 of 20 sera showed some reactivity in the idiotype
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ELISA for SDZ 89-109 (range, 0.04-0.24 JLg/ml). None of
the five CMV-positive patients who received SDZ-104 had
detectableidiotype in their serum before start of treatment.
One of the three seropositive patients treated with SDZ 89-
109had 0.3 JLg/ml of the respective idiotypein his pretreat-
mentserum. Inaddition, theseraof twoseronegative patients
also had lowidiotypic concentrations (0.01 and 0.10 JLg/ml).
Astheselevels werefar below thoseobserved after adminis-
trationof the twoantibodies, endogenous levels seem not to
interferewith the detection of therapeutically administered
antibody.
Administration oftheantibodies resulted in a rapidincrease
of the respective idiotype (figure 1). Peak serum and trough
levels are shown in table 1. The half-life of either compound
was 3-14 days (average, rv6; table 1). Neutralizing activity
in the serum increasedafter treatment in all patients receiv-
ingthe higherdosesof SDZ 89-109, whereaslowerdosesled
to only a marginal increase of CMV neutralizing serum ac-
tivities. A significant correlationwasobservedbetween con-
centrations of antibody measuredby the antiidiotype ELISA
and the neutralizing activity (r = .7, P < .001) in patients
treatedwith SDZ 89-109. Only minor increments were seen
in thepatients treated with2 mg/kg SDZ 89-104. Theincrease
observedafter treatmentwith the lowerdoseof this antibody
cannotbe attributedsolelyto therapy as all threepatients had
laboratory evidence ofCMVinfection duringthestudyperiod.
Neither clinical nor laboratory evidence of any acute or
chronictoxicity of eitherantibody wasobserved. Vital signs
and cardiac, pulmonary, liver,and kidney function were not
alteredbythe treatment (data not shown). Nocirculating im-
munecomplexes or evidence forcomplement activation were
detectable. Hematologic reconstitution occurred in patients
treated withantibodies within thesametimerangeas reported
in the literatureandobservedinhistoriccontrolsat our insti-
tution.
Discussion
This study showed that human monoclonal neutralizing
antibodies for CMVcan be safely administered to BMT re-
cipients and thathighserumlevels ofantibodies are achieved
bybiweekly administration overa 3-month periodafter trans-
plantation. Moreover, these high serum levels were closely
accompanied by increased neutralizing activity againstCMV
in patients treated with SDZ 89-109.
The elimination half-lives of human monoclonal antibod-
ies were1'\.16 days. Thusthe serumhalf-lives ofhumanmono-
clonalantibodies are considerably longerthanthosereported
after administration ofmurinemonoclonal antibodies, where
half-lives of 1'\.115 h after a singleinfusionwereobserved[4].
In investigations using mouse-human chimeric antibodies,
half-lives werecomparable to thoseofthe twoantibodies used
idiotype SOZ 89-104 !I.1g/ml)
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Figure 1. Idiotype levels (mean ± SE) of monoclonal antibodies SDZ 89-104 or SDZ 89-109 in serum before and within 14 days of
first infusion of 0.5 mg/kg of the antibodies in bone marrow transplant patients.
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in our study [11]. Although humanIgG has been reportedas
beingeliminated muchmoreslowly thanSDZ89-104 and89-
109witha {j half-life of20 days, thehalf-lives ofCMV-specific
IgG measuredafter treatment of BMT recipients with anti-
CMV hyperimmunoglobulin were similar to those observed
with SDZ 89-109 and 89-104 [12, 13].
Two mechanisms mightcontributeto theacceleratedclear-
ance of both the CMV-specific monoclonal antibodies and
CMV-specific IgG in BMT patients: First, such patients are
in a highly catabolic state during the posttransplant period
andaccelerated elimination mighttherefore merelyreflect en-
hanced protein turnover [14]. Second, the presence of viral
antigens due to persistent infectionwith CMV might lead to
specific bindingof antibodiesand thereby to an accelerated
elimination. Nevertheless, as half-lives did notdifferin clini-
cally asymptomatic seropositive and seronegative individu-
als, it seems unlikely that latent infectionwith CMV would
greatly influence the pharmacokinetics of the antibodies.
We conclude that it is feasible to maintain a high levelof
neutralizing antibodies against CMV in patients at risk for
CMV disease by administering CMV neutralizing human
monoclonal antibodies every second week. The efficacy of
such a regimen for the prophylaxis of CMV disease will be
tested in subsequent phase II trials.
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